Effector Therapeutics (EFTR.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share of -$2.16, previous value of -$6.00, expected value of -$2.16.
Effector Therapeutics (EFTR.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share of -$2.16, previous value of -$6.00, expected value of -$2.16.
EFFECTOR Therapeutics Q1 2024 GAAP EPS $(2.16) Beats $(2.17) Estimate; Reports Cash Runway Into Q1 Of 2025
eFFECTOR Therapeutics (NASDAQ:EFTR) reported quarterly losses of $(2.16) per share which beat the analyst consensus estimate of $(2.17) by 0.46 percent.
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersSensus Healthcare (NASDAQ:SRTS) shares increased by 33.3% to $5.08 during Thursday's after-market session. The market value of their outstanding shares is at $83.2 million. As per the news, the
10-Q: Quarterly report
Press Release: EFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update Dose escalation of zotatifin in the ZFA triplet ongoing at 0.14 mg/kg, with RP2D expected in H2 2024
EFFECTOR Therapeutics to Participate in Upcoming Investor Conference
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitor
Analysts Offer Insights on Healthcare Companies: Marinus (MRNS), UniQure (QURE) and EFFECTOR Therapeutics (EFTR)
Analysts Offer Insights on Healthcare Companies: EFFECTOR Therapeutics (EFTR), Adagene (ADAG) and Aquestive Therapeutics (AQST)
Trending Stocks Today: Candel Therapeutics Surges 121.64%
April 4th - US stocks trending in regular trading hours.Gainers: $Candel Therapeutics(CADL.US)$ surges 121.64% to $3.72 with a turnover of $214.01 million. $Allurion Technologies(ALUR.US)$ soars 92.48
Top Midday Decliners
eFFECTOR Therapeutics (EFTR) Chief Executive Officer Steve Worland said there is no "obvious path forward to continue developing tomivosertib in frontline NSCLC" based on the data currently available
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of STAAR Surgical Company (NASDAQ:STAA) rose sharply during Thursday's session after the company issued strong preliminary first-quarter net sales guidance. STAAR Surgical shares jumped 13.3%
BRNS, UPC and KWE Among Mid-day Movers
Effector Therapeutics Shares Plumb New Depths After Study Failure
By Colin Kellaher Effector Therapeutics shares collapsed on Thursday, tumbling 80% and hitting a new all-time low, after the clinical-stage biopharmaceutical company reported the failure of its lead
Nasdaq Surges 1%; ConAgra Brands Posts Upbeat Earnings
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 150 points on Thursday. The Dow traded up 0.49% to 39,319.03 while the NASDAQ rose 1% to 16,4340. The S&P
Cancer-Focused EFFECTOR Therapeutics Shelves Development Of Lung Cancer Candidate After Disappointing Data
Thursday, eFFECTOR Therapeutics Inc (NASDAQ:EFTR) released topline results from the primary analysis of the Phase 2 KICKSTART trial, which tested tomivosertib or placebo, each combined with Merck & Co
Dow Jumps Over 100 Points; US Jobless Claims Increase To 221,000
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.34% to 39,259.15 while the NASDAQ
EFFECTOR Therapeutics Shares Resume Trade
EFFECTOR Therapeutics Shares Resume Trade
EFFECTOR Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Down -83.2%
EFFECTOR Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Down -83.2%
EFFECTOR Therapeutics to End Development of Lung-Cancer Treatment Tomivosertib
By Adriano Marchese EFFECTOR Therapeutics said Thursday that it won't be moving forward with development of its tomivosertib lung cancer treatment after phase 2 data showed no positive trend. The ca
EFFECTOR Therapeutics to Resume Trading at 9 A.m. Following Disappointing Tomivosertib Data in NSCLC
No Data